PRO-PACT: Retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors

Guy Young, Guenter Auerswald, Victor Jimenez-Yuste, Thierry Lambert, Massimo Morfini, Elena Santagostino, Victor Blanchette

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Introduction: Hemophilia patients with inhibitors have frequent bleeding episodes and often develop hemophilic arthropathy which is in contradistinction to non-inhibitor patients for whom prophylaxis prevents joint disease. Recently, two prospective trials have demonstrated that secondary prophylaxis with bypassing agents in inhibitor patients offers benefit by reducing bleeding episodes. This report describes the clinical experience of secondary prophylaxis in a large population of inhibitor patients. Patients/Methods: This retrospective, observational study was performed by abstracting data from medical records of patients in whom secondary prophylaxis with rFVIIa was prescribed. Data were collected by professional medical record abstractors and included patient demographics, dosing regimens, bleeding events, and healthcare resource utilization. Data analysis was descriptive and included sensitivity analyses. Results: Data from 86 patients from 14 countries were collected. The primary outcome measure (% reduction in bleeding) was 46% (95% CI, -54.0 to - 38.2) in patients with at least one bleeding episodes prior to starting prophylaxis and 52% (95% CI, -60.7 to - 43.3) in patients with at least one bleeding episode per month prior to starting prophylaxis. A variety of subanalyses were performed, including among age and bleed location; the results for pediatric patients, adults, target and non-target joint bleeds categorizations were similar to the overall primary outcome. Conclusions: The results in this large observational study are similar to those from the previously reported prospective study of prophylaxis with rFVIIa in inhibitor positive patients, although this study represents a more typical inhibitor population who utilized prophylaxis in the clinical setting. As such, prophylaxis should be considered a potentially effective therapy in hemophilia patients with inhibitors.

Original languageEnglish
Pages (from-to)864-870
Number of pages7
JournalThrombosis Research
Volume130
Issue number6
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Hemophilia A
Observational Studies
Retrospective Studies
Hemorrhage
Joint Diseases
recombinant FVIIa
Medical Records
Population
Joints
Demography
Outcome Assessment (Health Care)
Prospective Studies

Keywords

  • Hemophilia
  • inhibitors
  • prophylaxis
  • recombinant factor VIIa

ASJC Scopus subject areas

  • Hematology

Cite this

PRO-PACT : Retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors. / Young, Guy; Auerswald, Guenter; Jimenez-Yuste, Victor; Lambert, Thierry; Morfini, Massimo; Santagostino, Elena; Blanchette, Victor.

In: Thrombosis Research, Vol. 130, No. 6, 12.2012, p. 864-870.

Research output: Contribution to journalArticle

Young, Guy ; Auerswald, Guenter ; Jimenez-Yuste, Victor ; Lambert, Thierry ; Morfini, Massimo ; Santagostino, Elena ; Blanchette, Victor. / PRO-PACT : Retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors. In: Thrombosis Research. 2012 ; Vol. 130, No. 6. pp. 864-870.
@article{ad5cc0ca15df4ca49670eb48c4535571,
title = "PRO-PACT: Retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors",
abstract = "Introduction: Hemophilia patients with inhibitors have frequent bleeding episodes and often develop hemophilic arthropathy which is in contradistinction to non-inhibitor patients for whom prophylaxis prevents joint disease. Recently, two prospective trials have demonstrated that secondary prophylaxis with bypassing agents in inhibitor patients offers benefit by reducing bleeding episodes. This report describes the clinical experience of secondary prophylaxis in a large population of inhibitor patients. Patients/Methods: This retrospective, observational study was performed by abstracting data from medical records of patients in whom secondary prophylaxis with rFVIIa was prescribed. Data were collected by professional medical record abstractors and included patient demographics, dosing regimens, bleeding events, and healthcare resource utilization. Data analysis was descriptive and included sensitivity analyses. Results: Data from 86 patients from 14 countries were collected. The primary outcome measure ({\%} reduction in bleeding) was 46{\%} (95{\%} CI, -54.0 to - 38.2) in patients with at least one bleeding episodes prior to starting prophylaxis and 52{\%} (95{\%} CI, -60.7 to - 43.3) in patients with at least one bleeding episode per month prior to starting prophylaxis. A variety of subanalyses were performed, including among age and bleed location; the results for pediatric patients, adults, target and non-target joint bleeds categorizations were similar to the overall primary outcome. Conclusions: The results in this large observational study are similar to those from the previously reported prospective study of prophylaxis with rFVIIa in inhibitor positive patients, although this study represents a more typical inhibitor population who utilized prophylaxis in the clinical setting. As such, prophylaxis should be considered a potentially effective therapy in hemophilia patients with inhibitors.",
keywords = "Hemophilia, inhibitors, prophylaxis, recombinant factor VIIa",
author = "Guy Young and Guenter Auerswald and Victor Jimenez-Yuste and Thierry Lambert and Massimo Morfini and Elena Santagostino and Victor Blanchette",
year = "2012",
month = "12",
doi = "10.1016/j.thromres.2012.08.305",
language = "English",
volume = "130",
pages = "864--870",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - PRO-PACT

T2 - Retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors

AU - Young, Guy

AU - Auerswald, Guenter

AU - Jimenez-Yuste, Victor

AU - Lambert, Thierry

AU - Morfini, Massimo

AU - Santagostino, Elena

AU - Blanchette, Victor

PY - 2012/12

Y1 - 2012/12

N2 - Introduction: Hemophilia patients with inhibitors have frequent bleeding episodes and often develop hemophilic arthropathy which is in contradistinction to non-inhibitor patients for whom prophylaxis prevents joint disease. Recently, two prospective trials have demonstrated that secondary prophylaxis with bypassing agents in inhibitor patients offers benefit by reducing bleeding episodes. This report describes the clinical experience of secondary prophylaxis in a large population of inhibitor patients. Patients/Methods: This retrospective, observational study was performed by abstracting data from medical records of patients in whom secondary prophylaxis with rFVIIa was prescribed. Data were collected by professional medical record abstractors and included patient demographics, dosing regimens, bleeding events, and healthcare resource utilization. Data analysis was descriptive and included sensitivity analyses. Results: Data from 86 patients from 14 countries were collected. The primary outcome measure (% reduction in bleeding) was 46% (95% CI, -54.0 to - 38.2) in patients with at least one bleeding episodes prior to starting prophylaxis and 52% (95% CI, -60.7 to - 43.3) in patients with at least one bleeding episode per month prior to starting prophylaxis. A variety of subanalyses were performed, including among age and bleed location; the results for pediatric patients, adults, target and non-target joint bleeds categorizations were similar to the overall primary outcome. Conclusions: The results in this large observational study are similar to those from the previously reported prospective study of prophylaxis with rFVIIa in inhibitor positive patients, although this study represents a more typical inhibitor population who utilized prophylaxis in the clinical setting. As such, prophylaxis should be considered a potentially effective therapy in hemophilia patients with inhibitors.

AB - Introduction: Hemophilia patients with inhibitors have frequent bleeding episodes and often develop hemophilic arthropathy which is in contradistinction to non-inhibitor patients for whom prophylaxis prevents joint disease. Recently, two prospective trials have demonstrated that secondary prophylaxis with bypassing agents in inhibitor patients offers benefit by reducing bleeding episodes. This report describes the clinical experience of secondary prophylaxis in a large population of inhibitor patients. Patients/Methods: This retrospective, observational study was performed by abstracting data from medical records of patients in whom secondary prophylaxis with rFVIIa was prescribed. Data were collected by professional medical record abstractors and included patient demographics, dosing regimens, bleeding events, and healthcare resource utilization. Data analysis was descriptive and included sensitivity analyses. Results: Data from 86 patients from 14 countries were collected. The primary outcome measure (% reduction in bleeding) was 46% (95% CI, -54.0 to - 38.2) in patients with at least one bleeding episodes prior to starting prophylaxis and 52% (95% CI, -60.7 to - 43.3) in patients with at least one bleeding episode per month prior to starting prophylaxis. A variety of subanalyses were performed, including among age and bleed location; the results for pediatric patients, adults, target and non-target joint bleeds categorizations were similar to the overall primary outcome. Conclusions: The results in this large observational study are similar to those from the previously reported prospective study of prophylaxis with rFVIIa in inhibitor positive patients, although this study represents a more typical inhibitor population who utilized prophylaxis in the clinical setting. As such, prophylaxis should be considered a potentially effective therapy in hemophilia patients with inhibitors.

KW - Hemophilia

KW - inhibitors

KW - prophylaxis

KW - recombinant factor VIIa

UR - http://www.scopus.com/inward/record.url?scp=84870245946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870245946&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2012.08.305

DO - 10.1016/j.thromres.2012.08.305

M3 - Article

C2 - 22964026

AN - SCOPUS:84870245946

VL - 130

SP - 864

EP - 870

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 6

ER -